Entinostat-Loaded PLGA Microparticles for Local Mesothelioma Therapy

Esti Stern – Ph.D Candidate, Hadassah Medical Center; Ori Wald, M.D., Ph.D., Head of minimally Invasive Thoracic Surgery Unit, Department of Cardiothoracic Surgery – Principal Investigator, Hadassah Medical Center& Faculty of Medicine, The Hebrew University of Jerusalem; Ofra Benny, Ph.D., Head of the Department of Pharmaceutics, – Principal Investigator, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem,

Introduction: Malignant Pleural Mesothelioma is an aggressive cancer with poor prognosis. The epigenetic modulator entinostat potentiates immunotherapy but suffers from systemic toxicity and poor local retention. We aimed to engineer a biodegradable drug delivery system to address this. This study focuses on the development and physicochemical optimization of Poly(lactic-coglycolic acid) (PLGA) microparticles designed for sustained, local release of entinostat within the pleural cavity.